Xuyu B. Zu
Hengyang, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 84 publications
LARS2 reprograms mitochondrial metabolism and epigenetically upregulates MHC-I to boost antitumor immunity in nasopharyngeal carcinoma.
Journal: Journal for immunotherapy of cancer
Published: August 05, 2026
EXPRESSION OF CONCERN: Intracellular FGF1 promotes invasion and migration in thyroid carcinoma via HMGA1 independent of FGF receptors.
Journal: Endocrine connections
Published: May 20, 2026
Enhanced hippocampal miR-32-5p promotes neuronal hyperexcitability and epileptic seizures by targeting KCC2.
Journal: European journal of pharmacology
Published: March 23, 2026
Deubiquitinase UCH-L1 confers paclitaxel resistance via stabilizing PKM2 to promote glycolysis in triple-negative breast cancer.
Journal: Cell death & disease
Published: July 03, 2025
DCC-2036 induces repolarization of TAMs to M1 type and enhances CD8+ T cell immunity in TNBC.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: May 09, 2025
CCT196969 inhibits TNBC by targeting the HDAC5/RXRA/ASNS axis to down-regulate asparagine synthesis.
CCT196969 inhibits TNBC by targeting the HDAC5/RXRA/ASNS axis to down-regulate asparagine synthesis.
Journal: Journal of experimental & clinical cancer research : CR
Published: May 06, 2025
Lactylation: A new direction for tumor-targeted therapy.
Journal: Biochimica et biophysica acta. Reviews on cancer
Published: March 25, 2025
Targeting kinases that regulate programmed cell death: a new therapeutic strategy for breast cancer.
Targeting kinases that regulate programmed cell death: a new therapeutic strategy for breast cancer.
Journal: Journal of translational medicine
Published: December 09, 2024
ZBTB7A as a therapeutic target for cancer.
Journal: Biochemical and biophysical research communications
Published: August 13, 2024
Last Updated: 09/26/2026